Your browser doesn't support javascript.
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Maio, Michele; Hamid, Omid; Larkin, James; Covre, Alessia; Altomonte, Maresa; Calabrò, Luana; Vardhana, Santosh A; Robert, Caroline; Ibrahim, Ramy; Anichini, Andrea; Wolchok, Jedd D; Giacomo, Anna Maria Di.
  • Maio M; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy. mmaiocro@gmail.com.
  • Hamid O; NIBIT Foundation Onlus, Genova, Italy.
  • Larkin J; The Angeles Clinic and Research Institute, Los Angeles, California.
  • Covre A; The Royal Marsden Hospital, London, United Kingdom.
  • Altomonte M; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
  • Calabrò L; Toscana Life Sciences Foundation, Siena, Italy.
  • Vardhana SA; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
  • Robert C; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy.
  • Ibrahim R; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.
  • Anichini A; Department of Medicine, Gustave Roussy and Paris-Saclay University, Villejuif, France.
  • Wolchok JD; Parker Institute For Cancer Immunotherapy, San Francisco, California.
  • Giacomo AMD; Human Tumor Immunobiology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
Clin Cancer Res ; 26(16): 4201-4205, 2020 08 15.
Article in English | MEDLINE | ID: covidwho-599654
ABSTRACT
The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Antineoplastic Agents, Immunological / Neoplasms Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Cancer Res Journal subject: Neoplasms Year: 2020 Document Type: Article Affiliation country: 1078-0432.CCR-20-1657

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus / Antineoplastic Agents, Immunological / Neoplasms Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Cancer Res Journal subject: Neoplasms Year: 2020 Document Type: Article Affiliation country: 1078-0432.CCR-20-1657